GLPBio

Cell Cycle/Checkpoint

Cell Cycle/Checkpoint

Cell Cycle

Cells undergo a complex cycle of growth and division that is referred to as the cell cycle. The cell cycle consists of four phases, G1 (GAP 1), S (synthesis), G2 (GAP 2) and M (mitosis). DNA replication occurs during S phase. When cells stop dividing temporarily or indefinitely, they enter a quiescent state called G0.

Research Areas

Products Related to Cell Cycle/Checkpoint(1539)

  • GC74326 structure
    GC74326MPSD TFA
    Purity: >98.00%

    MPSD TFA (marcks - ed TFA) est la forme de sel de TFA de mpsd.

  • GC74519 structure
    GC74519Cantuzumab ravtansine
    CAS: 868747-45-9
    Purity: >98.00%

    Cantuzumab ravtansine (imgn242; huc242 - dm4) est un ADC, un anticorps monoclonal humanisé, huc242, lié de manière covalente au dm4 (dm4) par une liaison disulfure.

  • GC74533 structure
    GC74533Tusamitamab ravtansine
    CAS: 2254086-60-5
    Purity: >99.00%

    Tusamitamab ravtansine (SAR - 408701) est un ADC ciblé contre les cellules tumorales exprimant le ceacam5, composé d'un anticorps monoclonal humanisé anti - ceacam5 lié de manière covalente à un puissant agent cytotoxique de type médénoïde, le dm4, par un joint clivable.

  • GC74600 structure
    GC74600Cofetuzumab pelidotin
    CAS: 1869937-48-3
    Purity: >99.00%

    Cofetuzumab pelidotin (PF - 06647020) est un ADC ciblant ptk7 qui contient un anticorps monoclonal humanisé anti - ptk7 lié à la charge utile d'un inhibiteur des microtubules auristatine, auristatine - 0101, par un joint clivable à base de Valine - Citrulline (VC).

  • GC78758 structure
    GC78758Mal-Val-Lys-PAB-MMAE TFA
    Purity: >98.00%

    Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC.

  • GC78762 structure
    GC78762Trastuzumab-DM4
    Purity: >98.00%

    Trastuzumab -DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab with DM4 (sulfo-SPDB-DM4) via a cleavable linker.

  • GC78763 structure
    GC78763ADC Control Human IgG1-sulfo-SPDB-DM4
    Purity: >98.00%

    ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization.

  • GC78764 structure
    GC78764Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
    CAS: 3103526-19-5
    Purity: >97.50%

    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

  • GC78765 structure
    GC78765LP-6 TFA
    CAS: 1629741-09-8
    Purity: >98.00%

    LP-6 TFA is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs.

  • GC78766 structure
    GC78766N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)
    Purity: >98.00%

    N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.

  • GC78767 structure
    GC78767N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    Purity: >98.00%

    N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE and a DNA topoisomerase I inhibitor Exatecan, and an ADC linker composition.

  • GC78791 structure
    GC78791AMG-172
    Purity: >98.00%

    AMG-172 is an antibody-drug conjugate ( ADC ) composed of a fully human IgG1 monoclonal anti- CD27L antibody conjugated to DM1 via the non-cleavable linker MCC.

  • GC78798 structure
    GC78798NN3201
    Purity: >99.00%

    NN3201 is a c-Kit -targeting antibody-drug conjugate ( ADC ) with high affinity ( K D = 0.19 pM).

  • GC78956 structure
    GC78956MYCMI-7 hydrobromide
    CAS: 102537-38-2
    Purity: >95.00%

    MYCMI-7 hydrobromide is a potent and selective MYC/MYCN inhibitor, with a K d of 4 μM for MYC and an IC 50 of 10 μM for topoisomerase IIα ( Topoisomerase II α ).

  • GC78959 structure
    GC78959c-Myc NLS TFA
    Purity: >98.00%

    c-Myc NLS TFA is a non-canonical nuclear localization signal (NLS) derived from the oncoprotein c-Myc, with the sequence PAAKRVKLD and containing 3 basic amino acids.

  • GC78960 structure
    GC78960DL78
    CAS: 132993-79-4
    Purity: >99.00%

    DL78 is an effective anti-mitotic agent.

  • GC78995 structure
    GC78995ZY39
    CAS: 2999673-51-5
    Purity: >99.50%

    ZY39 is a Sa ClpP agonist.

  • GC79000 structure
    GC79000Q901 TFA
    Purity: >98.50%

    Q901 (CDK7-IN-21) TFA is a selective and potent CDK7 inhibitor with an IC 50 of 10 nM.

  • GC79004 structure
    GC79004PMV6-PEG4-BI2536
    Purity: >98.00%

    PMV6-PEG4-BI2536 is an RIPTAC-like bifunctional molecule that promotes the formation of the p53 Y 220C -PLK1 ternary complex ( EC 50 = 1.4 μM).

  • GC79008 structure
    GC79008WY165
    Purity: >99.00%

    WY165 is a bifunctional molecule comprising TR79, an activator of the mitochondrial protease complex caseinolytic protease P ( ClpP ), linked to desthiobiotin.

  • GC79009 structure
    GC79009Tubulin polymerization-IN-84
    CAS: 2982893-14-9
    Purity: >99.50%

    Tubulin polymerization-IN-84 inhibits tubulin polymerization by targeting the colchicine-binding pocket, with an IC 50 = 10.9 μM.

  • GC79010 structure
    GC79010DHTP
    CAS: 1620225-37-7
    Purity: >99.00%

    DHTP is a kinesin-13 family of microtubule depolymerases selective allosteric inhibitor that inhibits kinesin-13 ATPase activity and microtubule depolymerization activity.

  • GC79011 structure
    GC790117-Benzoyloxindole
    CAS: 51135-38-7
    Purity: >98.00%

    7-Benzoyloxindole (Compound 4a) is a tubulin destabilizer.

  • GC79012 structure
    GC79012Microtubule-IN-13
    Purity: >99.50%

    Microtubule-IN-13 (Compound FB2) is a microtubule inhibitor.